Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBT115301 in Healthy Participants
NCT05388981Phase 1Completed
- Sponsor
- Sonoma Biotherapeutics
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SBT115301 in autoimmune diseases (5 cohorts), sponsored by Sonoma Biotherapeutics. Primary endpoints: Adverse Events and Serious Adverse Events. Started Jul 2022; status: completed.
02
Drugs
SBT115301
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT05388981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388981.